

FDAMA STAKEHOLDER MEETING **APRIL 28, 1999**

Talking with Stakeholders About FDA Modernization

**Your question/comments will become part of Docket Number: 99N-0386 Fax to: 1-888-361-4011 (on April 28 only)

Title (required)	First Name (required)	Last Name (required)
□Dr. □ Mr. □Mrs. □XMs.	PE 664	DAVIS
Organization	hone	
Stakeholder Gro	oup ✓ stakeholder group	p you represent
☐ Consumer ☐	Consumer Group 🔾 H	Health Professional Industry Association Other
Center \(\square \) the	center/product area your o	comments address
☐ Center for Bio ☐ Center for Dev ☐ Center for Vet ☐ FDA General	rices and Radiological He	☐ Center for Drug Evaluation and Research ☐ Center for Food Safety and Applied Nutrition ☐ Office of Regulatory Affairs
Questions to Stakeholders		
Please check the question/commer	box next to the stakeholdent addresses.	er question/s from the March 22, 1999, Federal Register notice which you
□ 1. What act science	• What actions do you propose the Agency take to expand FDA's capability to incorporate state-of-the-art science into its risk-based decision-making?	
□ 2. What ac		
2 3. What ac	3. What actions do you propose for educating the public about the concept of balancing risks against benefits in public health decision-making?	
□ 4. What ac	ctions do you propose to e	nable FDA and its product centers to focus resources on areas of greatest
□ 5. What ad	risk to the public health? What additional actions do you propose for enhancing communication processes that allow for ongoing feedback and/or evaluation of our modernization efforts?	
	Additional Comments on FDA Modernization Efforts.	
	ENT/QUESTION	

Y

Unhalation of pragranced products is known to trigger authma and migraine headaches in some individuals.

The EPA names "the use of chemically formulated personal can products " along with perticides and household cleaners as contributors to indoor air pollution.

You do you propose to raise public awareness of possible perfects?

99N-0386